Faron Pharmaceuticals Ltd ("Faron") (AIM: FARN), announced on 5/8/17 top line data from its pan-European Phase III INTEREST trial. The INTEREST study did not meet the Day 28 (D28) primary efficacy... read more
Faron Pharmaceuticals Ltd ("Faron") (AIM: FARN), announced on 5/8/17 top line data from its pan-European Phase III INTEREST trial. The INTEREST study did not meet the Day 28 (D28) primary efficacy... read more
Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) announced on 5/8/18 that, following the receipt of minutes from a recent meeting with the U.S. Food and Drug Administration (FDA), the Company has... read more
Neon Therapeutics, announced on 5/8/18 that it has treated the first patient in a clinical trial evaluating its proprietary personal neoantigen vaccine, NEO-PV-01, in combination with Merck’s anti... read more
Horizon Pharma plc (Nasdaq:HZNP) announced on 5/8/18 that it has received two Notices of Allowance from the United States Patent and Trademark Office for U.S. patent application numbers 15/457,643... read more